Aligos Therapeutics (ALGS) Competitors $4.68 +0.11 (+2.41%) Closing price 04:00 PM EasternExtended Trading$4.64 -0.04 (-0.85%) As of 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALGS vs. PRQR, FDMT, NMRA, LRMR, NGNE, SCPH, OGI, ADCT, KOD, and TNXPShould you be buying Aligos Therapeutics stock or one of its competitors? The main competitors of Aligos Therapeutics include ProQR Therapeutics (PRQR), 4D Molecular Therapeutics (FDMT), Neumora Therapeutics (NMRA), Larimar Therapeutics (LRMR), Neurogene (NGNE), scPharmaceuticals (SCPH), Organigram (OGI), ADC Therapeutics (ADCT), Kodiak Sciences (KOD), and Tonix Pharmaceuticals (TNXP). These companies are all part of the "pharmaceutical products" industry. Aligos Therapeutics vs. ProQR Therapeutics 4D Molecular Therapeutics Neumora Therapeutics Larimar Therapeutics Neurogene scPharmaceuticals Organigram ADC Therapeutics Kodiak Sciences Tonix Pharmaceuticals Aligos Therapeutics (NASDAQ:ALGS) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, community ranking, media sentiment and earnings. Does the media prefer ALGS or PRQR? In the previous week, ProQR Therapeutics had 8 more articles in the media than Aligos Therapeutics. MarketBeat recorded 8 mentions for ProQR Therapeutics and 0 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 1.89 beat ProQR Therapeutics' score of 0.84 indicating that Aligos Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Aligos Therapeutics Very Positive ProQR Therapeutics Positive Which has more volatility & risk, ALGS or PRQR? Aligos Therapeutics has a beta of 2.72, meaning that its stock price is 172% more volatile than the S&P 500. Comparatively, ProQR Therapeutics has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500. Is ALGS or PRQR more profitable? ProQR Therapeutics has a net margin of -134.31% compared to Aligos Therapeutics' net margin of -1,283.19%. ProQR Therapeutics' return on equity of -71.58% beat Aligos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aligos Therapeutics-1,283.19% -114.34% -64.58% ProQR Therapeutics -134.31%-71.58%-19.70% Do analysts prefer ALGS or PRQR? Aligos Therapeutics presently has a consensus target price of $70.00, indicating a potential upside of 1,395.73%. ProQR Therapeutics has a consensus target price of $9.50, indicating a potential upside of 733.33%. Given Aligos Therapeutics' higher possible upside, equities research analysts plainly believe Aligos Therapeutics is more favorable than ProQR Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aligos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00ProQR Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Do insiders & institutionals believe in ALGS or PRQR? 60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are owned by institutional investors. 8.8% of Aligos Therapeutics shares are owned by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has preferable earnings & valuation, ALGS or PRQR? ProQR Therapeutics has higher revenue and earnings than Aligos Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAligos Therapeutics$3.95M7.25-$87.68M-$20.90-0.22ProQR Therapeutics$18.91M6.34-$30.43M-$0.34-3.35 Does the MarketBeat Community favor ALGS or PRQR? ProQR Therapeutics received 307 more outperform votes than Aligos Therapeutics when rated by MarketBeat users. However, 67.44% of users gave Aligos Therapeutics an outperform vote while only 61.99% of users gave ProQR Therapeutics an outperform vote. CompanyUnderperformOutperformAligos TherapeuticsOutperform Votes2967.44% Underperform Votes1432.56% ProQR TherapeuticsOutperform Votes33661.99% Underperform Votes20638.01% SummaryProQR Therapeutics beats Aligos Therapeutics on 11 of the 19 factors compared between the two stocks. Remove Ads Get Aligos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALGS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALGS vs. The Competition Export to ExcelMetricAligos TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$28.61M$2.84B$5.29B$7.34BDividend YieldN/A1.90%5.11%4.31%P/E Ratio-0.3530.4821.7117.76Price / Sales7.25441.91379.1297.68Price / CashN/A168.6838.1534.64Price / Book0.153.466.433.98Net Income-$87.68M-$72.06M$3.21B$247.44M7 Day Performance17.29%6.38%5.23%4.43%1 Month Performance-59.90%-17.51%-9.53%-7.73%1 Year Performance-76.21%-27.84%10.99%1.28% Aligos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALGSAligos Therapeutics4.0342 of 5 stars$4.68+2.4%$70.00+1,395.7%-78.1%$28.61M$3.95M-0.3590Positive NewsPRQRProQR Therapeutics2.1894 of 5 stars$1.17-0.8%$9.50+712.0%-43.0%$123.10M$18.91M-3.66180Short Interest ↓News CoverageFDMT4D Molecular Therapeutics2.5801 of 5 stars$2.65-4.3%$26.71+908.1%-89.1%$122.70M$37,000.00-0.93120Analyst RevisionPositive NewsGap DownNMRANeumora Therapeutics3.1818 of 5 stars$0.75+2.3%$9.29+1,132.8%-94.3%$122.00MN/A-0.40108LRMRLarimar Therapeutics3.294 of 5 stars$1.87-4.6%$19.63+949.5%-74.6%$119.73MN/A-1.6330Positive NewsNGNENeurogene2.1271 of 5 stars$7.86-10.6%$53.00+574.3%-69.4%$117.35M$925,000.00-1.8490Analyst ForecastGap DownHigh Trading VolumeSCPHscPharmaceuticals3.7591 of 5 stars$2.33+0.4%$14.00+500.9%-45.4%$117.16M$36.33M-1.2330Short Interest ↓Gap DownOGIOrganigram0.5614 of 5 stars$0.92-2.7%N/A-44.7%$116.74M$166.12M-2.43860Positive NewsADCTADC Therapeutics2.1457 of 5 stars$1.17-1.3%$7.75+565.2%-73.9%$115.43M$70.84M-0.49310Gap DownKODKodiak Sciences3.6526 of 5 stars$2.18-7.2%$9.00+312.8%-39.3%$114.99MN/A-0.6090Short Interest ↑TNXPTonix Pharmaceuticals2.5354 of 5 stars$17.80+13.8%$585.00+3,186.5%-96.7%$114.54M$10.09M0.0050 Remove Ads Related Companies and Tools Related Companies ProQR Therapeutics Competitors 4D Molecular Therapeutics Competitors Neumora Therapeutics Competitors Larimar Therapeutics Competitors Neurogene Competitors scPharmaceuticals Competitors Organigram Competitors ADC Therapeutics Competitors Kodiak Sciences Competitors Tonix Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALGS) was last updated on 4/17/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aligos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aligos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALGS Stock Free ALGS Stock Alerts